Download MendeleyMTA-cooperative PRMT5 inhibitors from cofactor-directed DNA-encoded library screens.
Andersson, J., Cowland, S., Vestergaard, M., Yang, Y., Liu, S., Fang, X., Mukund, S., Ghimire-Rijal, S., Carter, C., Chung, G., Jacso, T., Sarvary, I., Hughes, P.E., Gouliaev, A., Payton, M., Belmontes, B., Caenepeel, S., Franch, T., Glad, S., Husemoen, B., Nielsen, S.J.(2025) Proc Natl Acad Sci U S A 122: e2425052122-e2425052122
- PubMed: 40377999 Search on PubMedSearch on PubMed Central
- DOI: https://doi.org/10.1073/pnas.2425052122
- Primary Citation Related Structures:
9NWY - PubMed Abstract:
Methylthioadenosine phosphorylase ( MTAP ) gene deletions are frequent in human cancers. Loss of MTAP leads to significantly increased cellular levels of methylthioadenosine (MTA), a cellular metabolite and specific inhibitor of the cell-essential enzyme Protein Arginine Methyltransferase-5 (PRMT5). Using a cofactor-directed screening strategy and DNA-encoded libraries, we identify a class of PRMT5 inhibitors that cooperatively inhibit PRMT5 in the presence of MTA. An optimized inhibitor, AM-9934, selectively inhibits PRMT5 in MTAP -deleted cells and in transplanted tumors while sparing MTAP -expressing counterparts, leading to specific suppression of viability in MTAP -deleted cells. Structural studies show that AM-9934 occupies the arginine substrate pocket of MTA-bound PRMT5. This study introduces a broadly applicable method for directed DNA-encoded library screening toward a desired mechanistic outcome and highlights MTA-selective PRMT5 inhibition as an attractive therapeutic strategy with a potentially broad therapeutic index in patients with MTAP -deleted cancers.
- Amgen Research, Copenhagen DK-2100, Denmark.
Organizational Affiliation:
